News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
The Journal of Experimental Medicine – Important roles of STAG2 in suppressing lung tumorigenesis
Lung Cancer/X
Dec 12, 2024, 20:39

The Journal of Experimental Medicine – Important roles of STAG2 in suppressing lung tumorigenesis

The Journal of Experimental Medicine shared on X:

“Emily Ashkin et al underscore important roles of STAG2 in suppressing lung tumorigenesis and highlight a STAG2-PAXIP1/PAGR1 tumor-suppressive program that may transcend cancer type. ”

The Journal of Experimental Medicine - Important roles of STAG2 in suppressing lung tumorigenesis

A STAG2-PAXIP1/PAGR1 axis suppresses lung tumorigenesis | Journal of Experimental Medicine | Rockefeller University Press

Authors: Emily L. Ashkin, Yuning J. Tang, Haiqing Xu, King L. Hung, Julia A. Belk, Hongchen Cai, Steven S. Lopez, Deniz Nesli Dolcen, Jess D. Hebert, Rui Li, Paloma A. Ruiz, Tula Keal, Laura Andrejka, Howard Y. Chang, Dmitri A. Petrov, Jesse R. Dixon, Zhichao Xu, Monte M. Winslow.

The Journal of Experimental Medicine - Important roles of STAG2 in suppressing lung tumorigenesis

cancer Deniz Nesli Dolcen Dmitri A. Petrov Emily Ashkin Emily L. Ashkin Haiqing Xu Hongchen Cai Howard Y. Chang Jess D. Hebert Jesse R. Dixon Julia A. Belk King L Hung Laura Andrejka Monte M. Winslow OncoDaily Oncology Paloma A. Ruiz Rui Li Steven S. Lopez The Journal of Experimental Medicine Tula Keal Yuning J. Tang Zhichao Xu
Special Coverage
Blog
Dec 12, 2024, 20:39
The Journal of Experimental Medicine - Important roles of STAG2 in suppressing lung tumorigenesis
Blog
Dec 12, 2024, 20:39
Mechanisms of Obesity Related Risk for Breast Cancer and Approaches to Risk Reduction
Blog
Dec 12, 2024, 20:39
Ada Waks on the management of small HER2+ breast cancers
Blog
Dec 12, 2024, 20:39
Imlunestrant + abemaciclib likely to become a new 2L treatment option for HR+/HER2- Metastatic breast cancer
Blog
Dec 12, 2024, 20:39
Paolo Tarantino: SHR-A1811 x8 +/- pyrotinib vs TCHP for stage III HER2+ early breast cancer
Blog
Dec 12, 2024, 20:39
Gov. Healey Passes Law Allowing Non-U.S. Physicians To Practice In State
Blog
Dec 12, 2024, 20:39
ESMO - RCTs have been instrumental in establishing immunotherapy with ICIs for treating Advanced Solid Cancer
Blog
Dec 12, 2024, 20:39
Zainab Shinkafi-Bagudu: Sharing information on how survivors can access the help they need
Insight
Dec 12, 2024, 20:39
Arya Roy: Our article exploring the pros and cons of academia, community and hybrid practices
Blog
Dec 12, 2024, 20:36
Patrick Hwu: Thank you to all who contributed on Giving Tuesday to support cancer research
Blog
Dec 12, 2024, 20:33
Yakup Ergün: ESMO Magnitude of Clinical Benefit Scale
Insight
Dec 12, 2024, 20:30
Aditi Shastri: Our review on therapeutic interventions and early clinical trials in CH